Therapeutic drug monitoring (tdm) for antituberculosis treatment safety: screening for isoniazid acetylator phenotype.

• In: SIG Bioavailability / Bioequivalence - Poster Session
• At: Salvadore (Brazil) (2006)
• Type: Poster
• Poster code: BB-P-008
• By: GONCALVES, J.C. (Fac Farmácia-UFRJ, Rio De Janeiro, Brazil)
• Co-author(s): Neves de Miranda, Claudia (Fac Farmácia-UFRJ, RIO DE JANEIRO, Brazil)
  Carvalho Queiroz Melo, Fernanda (Fac. de Medinina - UFRJ, RIO DE JANEIRO, Brazil)
  
• Abstract:

  Tuberculosis is the world’s second commonest cause of death from infectious disease, after HIV/AIDS. In Brazil, there were an estimated 116.000 new cases of tuberculosis in 2003. Regimens containing isoniazid (INH), rifampicin and pirazinamide are traditionally used first-line therapy for tuberculosis. However, acute or chronic hepatitis..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login